Childhood cognitive control as a predictor of long-term clinical and functional outcomes in Tourette syndrome.

J Child Psychol PsychiatryApr 21, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Kathryn E Barber, Emily J Ricketts, Douglas W Woods et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the role of childhood cognitive control in predicting long-term outcomes in 80 individuals with Tourette syndrome (TS). The study found that better childhood cognitive control, including inhibition and processing speed, was associated with lower tic severity and higher quality of life in early adulthood, with significant results maintained after adjusting for comorbidities.

Key findings

  • Greater inhibition and processing speed in childhood predicted lower tic severity and impairment in early adulthood.
  • Higher odds of tic remission were associated with better childhood cognitive control.
  • Improved working memory and response flexibility correlated with higher educational attainment and income.

Why it matters

Understanding the predictors of long-term outcomes in Tourette syndrome can inform treatment strategies and interventions. Enhancing cognitive control in childhood may improve clinical and functional trajectories for individuals with TS.

Source

Published in J Child Psychol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.